Current US Food and Drug Administration-Approved Pharmacologic Therapies for the Treatment of Irritable Bowel Syndrome with Diarrhea

Efficacy and Safety of Eluxadoline in Patients With Irritable Bowel Syndrome With Diarrhea Who Report Inadequate Symptom Control With Loperamide

(2019) Darren M. Brenner et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome

(2018) Alexander C. Ford et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Risk of Pancreatitis Following Treatment of Irritable Bowel Syndrome With Eluxadoline

(2018) Andrew J. Gawron et al.   Clinical Gastroenterology and Hepatology

Beneficial effects of Rifaximin in post-infectious irritable bowel syndrome mouse model beyond gut microbiota

(2018) Yu Jin et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea

(2017) Jessica L. Buono et al.   Health and Quality of Life Outcomes

Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea

(2016) Brooks D Cash et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome

(2016) Anthony Lembo et al.   GASTROENTEROLOGY

Bowel Disorders

(2016) Brian E. Lacy et al.   GASTROENTEROLOGY

The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: a Rome Foundation working team literature review

(2016) Ami D Sperber et al.   GUT

Eluxadoline for Irritable Bowel Syndrome with Diarrhea

(2016) Anthony J. Lembo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials

(2014) P. Schoenfeld et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers

(2014) Wakako Fujita et al.   BIOCHEMICAL PHARMACOLOGY

Rifaximin Alters Intestinal Bacteria and Prevents Stress-Induced Gut Inflammation and Visceral Hyperalgesia in Rats

(2013) Dabo Xu et al.   GASTROENTEROLOGY

A 9-year evaluation of temporal trends in alosetron postmarketing safety under the risk management program

(2013) Kenneth Tong et al.   Therapeutic Advances in Gastroenterology

Evaluation of Harm in the Pharmacotherapy of Irritable Bowel Syndrome

(2012) Eric Shah et al.   AMERICAN JOURNAL OF MEDICINE

Modulation of gastrointestinal function by MuDelta, a mixed µ opioid receptor agonist/ µ opioid receptor antagonist

(2012) PR Wade et al.   BRITISH JOURNAL OF PHARMACOLOGY

Global Prevalence of and Risk Factors for Irritable Bowel Syndrome: A Meta-analysis

(2012) Rebecca M. Lovell et al.   Clinical Gastroenterology and Hepatology

Inhibition of NF-κB by a PXR-dependent pathway mediates counter-regulatory activities of rifaximin on innate immunity in intestinal epithelial cells

(2011) Andrea Mencarelli et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation

(2011) Mark Pimentel et al.   NEW ENGLAND JOURNAL OF MEDICINE